Dendreon Corp fka DNDNQ

[stuck_holder]

Anyone have a spare $2,750?


To date, no active specific immunotherapies (specifically targeted to a type of cancer) have been approved by the FDA. The most advanced example is Dendreon’s Provenge. Dendreon is submitting a rolling BLA (Biologics License Application) to the FDA for Provenge, for treatment of advanced hormone-refractory prostate cancer. Clinical trial data supporting this BLA, and available data on other cancer immunotherapies and vaccine, are discussed in the report. The report also includes interviews with experts in the field of cancer immunotherapies and vaccines, who discuss the progress, and the challenges and hurdles,faced by researchers and companies working in this emerging field.


http://www.advancesreports.com/ExecSum/CancerIM%20Exec%20Sum.pdf